{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal AstroStem-V",
            "NStudiesAvail": 430108,
            "NStudiesFound": 25,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 25,
            "FieldList": [
                  "MaximumAge",
                  "MinimumAge",
                  "NCTId",
                  "NCTIdAlias",
                  "OfficialTitle",
                  "OrgClass",
                  "OrgFullName",
                  "OrgStudyId",
                  "OrgStudyIdDomain",
                  "OrgStudyIdLink",
                  "OrgStudyIdType",
                  "OtherEventAssessmentType",
                  "OtherEventNotes",
                  "OtherEventOrganSystem",
                  "OtherEventSourceVocabulary"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "MaximumAge": [
                              "85 Years"
                        ],
                        "MinimumAge": [
                              "50 Years"
                        ],
                        "NCTId": [
                              "NCT04228666"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBALZ01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 2,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "19 Years"
                        ],
                        "NCTId": [
                              "NCT04527224"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase I/\u2161a Trial to Explore the Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell (AstroStem-V) Therapy in Patients With COVID-19 Pneumonia"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Nature Cell Co. Ltd."
                        ],
                        "OrgStudyId": [
                              "ASVP1N2A-US"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 3,
                        "MaximumAge": [],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT04349631"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBCOV01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 4,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03691909"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBRA01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "OtherEventNotes": [
                              "Rheumatoid Arthritis Flare/Worsening of RA",
                              "Staph Infection",
                              "Diffuse Rash/Rash on Abdomen",
                              "Shortness of Breath",
                              "Bowel Blockage",
                              "Anemia/Anemia Chronic Disease",
                              "Renal Insufficiency",
                              "Right Eyelid Pruritis",
                              "Cyst Right Ear",
                              "Neck Spasm"
                        ],
                        "OtherEventOrganSystem": [
                              "Immune system disorders",
                              "Skin and subcutaneous tissue disorders",
                              "Skin and subcutaneous tissue disorders",
                              "Respiratory, thoracic and mediastinal disorders",
                              "Gastrointestinal disorders",
                              "Blood and lymphatic system disorders",
                              "Vascular disorders",
                              "Blood and lymphatic system disorders",
                              "Infections and infestations",
                              "Renal and urinary disorders",
                              "Eye disorders",
                              "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                              "Musculoskeletal and connective tissue disorders",
                              "Infections and infestations",
                              "Surgical and medical procedures"
                        ],
                        "OtherEventSourceVocabulary": [
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT",
                              "SNOMED CT"
                        ]
                  },
                  {
                        "Rank": 5,
                        "MaximumAge": [],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT04087889"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Individual Patient Expanded Access IND of Hope Biosciences Allogeneic First Blood Relative Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBPC01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 6,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04289194"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Phase 1/2 Clinical Study to Assess the Feasibility, Safety, Tolerability and Preliminary Efficacy of the Administration of HCR040, Allogeneic Adipose-derived Adult Mesenchymal Stem Cells, in Acute Respiratory Distress Syndrome"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Histocell, S.L."
                        ],
                        "OrgStudyId": [
                              "ALICELL-CT-01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 7,
                        "MaximumAge": [],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT04348435"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBCOV02"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 8,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03925649"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Individual Patient Expanded Access IND (Investigational New Drug) of Autologous HB-adMSCs for the Treatment of Spinal Cord Injury"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBSCI01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 9,
                        "MaximumAge": [],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT04362189"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBCOV03"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 10,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "3 Years"
                        ],
                        "NCTId": [
                              "NCT04029896"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Individual Patient Expanded Access IND of Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBCP01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 11,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "45 Years"
                        ],
                        "NCTId": [
                              "NCT04995081"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBPD04"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 12,
                        "MaximumAge": [
                              "55 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04063215"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBTBI01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 13,
                        "MaximumAge": [
                              "75 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT05116540"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Randomized, Double-Blind, Single-Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBMS01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 14,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04064957"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cell Therapy for Chronic Spinal Cord Injury"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBSCI02"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 15,
                        "MaximumAge": [
                              "75 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04928287"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "\"A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease\""
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBPD03"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 16,
                        "MaximumAge": [],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT04604288"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Individual Patient Expanded Access IND to Evaluate the Safety and Preliminary Efficacy of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBKP01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 17,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT05126563"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Randomized, Double-blinded, Single-center, Phase 2 Efficacy, and Safety Study of Allogeneic HB-adMSCs for the Treatment of Patients With Chronic Post-COVID-19 Syndrome."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBPCOVID02"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 18,
                        "MaximumAge": [],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT04514952"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBALS01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 19,
                        "MaximumAge": [
                              "95 Years"
                        ],
                        "MinimumAge": [
                              "76 Years"
                        ],
                        "NCTId": [
                              "NCT04772378"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "An Intermediate Size Patient Population Expanded Access IND to Evaluate the Safety of Autologous HB-adMSCs for the Treatment of Patients With Parkinson's Disease."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBPD05"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 20,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04798066"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Patients With Post-COVID-19 Syndrome."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBPCOV01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 21,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04711811"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Individual Patient Expanded Access IND Using HB-adMSCs for the Treatment of Chronic Musculoskeletal Pain."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBCMP01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 22,
                        "MaximumAge": [],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT04825626"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "An Expanded Access IND to Evaluate the Safety and Preliminary Efficacy of Autologous HB-adMSCs for the Treatment of a Single Patient With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBCIDP01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 23,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04825613"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "\"Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Primary Lateral Sclerosis\""
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBPLS01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 24,
                        "MaximumAge": [],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT04064983"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "An Expanded Access IND to Evaluate the Safety and Efficacy of Autologous HB-adMSCs for the Treatment of a Single Patient With Polyneuropathy"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBPN01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 25,
                        "MaximumAge": [],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT05154851"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "An Expanded Access IND to Evaluate the Safety and Efficacy of Autologous HBadMSCs for the Treatment of a Single Pediatric Patient With Congenital Muscular Dystrophy."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBCMD01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  }
            ]
      }
}